Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate

Santos, Priscilla de Nazaré Silva dos; Souza, Aglécio Luiz de; Batista, Gisele Almeida; Melhado-Kimura, Vaneska; Lima, Gabriel Alves da Costa; Bahamondes, Luís; Fernandes, Arlete

doi:10.1007/s00404-016-4192-9

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risk of bias was rated as "moderate" most frequently for attrition greater than 20% or not controlling for potential confounding by activity level or diet (Appendix 6, http://links.lww.com/ AOG/B253); these are two lifestyle variables that can correspond to both contraceptive method choice and to weight gain. Four studies 15,[23][24][25] found DMPA users had statistically significant increases in weight, BMI, or body fat mass compared with Cu-IUD or other nonhormonal method users, and two studies 21,22 found no statistically significant difference in change in BMI or body fat between DMPA and Cu-IUD users. The study by Batista et al found that DMPA users and Cu-IUD users had similar mean weight at baseline (62 kg vs 61 kg, respectively, P5.54), but at 1-year follow-up, DMPA users had statistically significantly higher mean weight than Cu-IUD users (DMPA 65 kg vs Cu-IUD 62 kg, P,.001).…”

Section: Resultsmentioning

confidence: 98%

“…Two factors downgraded the study to "fair": 1) either intentionally [21][22][23] or unintentionally 15,[24][25][26][27][28] excluding women of obese body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) or 2) being conducted in a country other than the United States [21][22][23][25][26][27][28][29][30][31][32][33][34][35] or from a small subpopulation in the United States, 36 making the study population less generalizable to the U.S. primary care population.…”

Section: Resultsmentioning

confidence: 99%

“…25 Dos Santos et al found no statistically significant differences in change of BMI at 1 year between DMPA and Cu-IUD users. 21,22 With respect to body composition, Bonny et al found that DMPA users had a total body fat increase of 10.3% over 6 months, whereas nonhormonal method users had a total body fat decrease of 0.7% (P5.04). 15 Clark et al similarly found a statistically significant increase in fat mass, along with an increase in central-to-peripheral fat mass ratio, in DMPA users over 2.5 years compared with no change in nonhormonal method users; duration of DMPA use was the strongest predictor of these outcomes.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate

Dianat¹,

Fox²,

Ahrens³

et al. 2019

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

OBJECTIVE: Counseling about potential side effects and health benefits of contraceptive methods could facilitate continued method use and method satisfaction, yet no evidence-based compilation of side effects and benefits exists to aid such counseling. Among contraceptive methods in the United States, depot medroxyprogesterone acetate (DMPA) injectables have the highest discontinuation rates, and most discontinuation is attributable to side effects. This review examines the side effects and health benefits of DMPA to inform counseling. DATA SOURCES: We searched PubMed, POPLINE, EMBASE, Web of Science, Campbell Collaboration Library of Systematic Reviews, the Cochrane Database of Systematic Reviews, the Cochrane Center Register of Controlled Trials, and ClinicalTrials.gov. METHODS OF STUDY SELECTION: We included English-language studies published from 1985 to 2016 that enrolled healthy, nonbreastfeeding females aged 13–49 years at risk of unintended pregnancy, compared intramuscular or subcutaneous progestin-only injectables to a contemporaneous comparison group, and addressed at least one key question: 1) What side effects are associated with progestin-only injectable contraceptive use? 2) What health benefits are associated with progestin-only injectable contraceptive use? Study quality was assessed using criteria from the U.S. Preventive Services Task Force. TABULATION, INTEGRATION, AND RESULTS: Twenty-four studies met inclusion criteria. None were randomized controlled trials. There were 13 prospective cohort, five retrospective cohort, four case–control, and two cross-sectional studies. Studies of moderate or high risk of bias suggest an association between DMPA use and weight gain, increased body fat mass, irregular bleeding, and amenorrhea. Inconsistent evidence exists for an association between DMPA use and mood or libido changes. Limited evidence exists for an association between DMPA use and decreased risk of cancers and tubal infertility. CONCLUSION: Higher-quality research is needed to clarify DMPA's side effects and benefits. In absence of such evidence, patient-centered counseling should incorporate the available evidence while acknowledging its limitations and recognizing the value of women's lived experiences.

show abstract

Section: Resultsmentioning

confidence: 98%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate

Dianat¹,

Fox²,

Ahrens³

et al. 2019

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…Secundariamente, o AMP-D pode reduzir as dores associadas à endometriose (17). Os possíveis efeitos colaterais relacionados ao uso deste método são irregularidade na menstruação, oscilação no humor e aumento de peso corporal (16,34,35). Esse método já foi associado com perda de massa óssea quando usado por tempo prolongado (32,36), entretanto os resultados dos estudos a respeito são conflitivos (37,38).…”

Section: Introductionunclassified

Alguns fatores associados ao uso de métodos intrauterinos e Acetato de Medroxiprogesterona de Depósito

Ferreira¹

View full text Add to dashboard Cite

Objective: To assess some clinical aspects of intrauterine contraceptives (IUCs), subdermal implants and depot modroxyprogesterone acetate (DMPA). Methods: We performed four studies: three were retrospectives and one was cross-sectional. In two studies we reviewed medical charts of women between 12-50 years of age in use of any long acting reversible contraceptive (LARC) method or DMPA. In the first study we compared the cumulative discontinuation rates for sterilization or menopause. In the second one, women were divided in two groups: those who received all injections at the clinic and those who received a subsequent dose to be injected at a clinic near their home. The efficacy rates, reasons for discontinuation and continuation rates were compared between the groups. In the third study, data from 15,030 new users of levonorgestrel releasing intrauterine system (LNG-IUS) was analysed and it was estimated the DALY averted using the mathematical model Impact 2. In the last study, women using the IUCs responded to the World Health Organization Quality of Life Questionnaire, Abbreviated Version (WHOQOL-BREF), the Female Sexual Function Index (FSFI) and a questionnaire formulated for this study concerning some aspects of the method in use. The final scores were compared between users of both methods. Results: Study 1. More women discontinued the use of methods to perform the sterilization in the initial studied period, however, from 20 to 30 years of use, women using the intrauterine contraceptives and DMPA started to discontinue the methods only when reaching the menopause. Study 2. Women who received the DMPA injections every three months at the clinic had greater pregnancy and discontinuation rates when compared to those who received the subsequent dose to be injected near their residence. Study 3. During the period of analysis, there was an estimated DALY averted of 486 live births, 14 combined maternal morbidity and mortality, 143 child mortalities and 410 unsafe abortions with the use of LNG-IUS. Study 4. A total of 122 copper IUD (Cu-IUD) users and 87 LNG-IUS users presented a score ≤26.55 on the FSFI questionnaire, indicating a risk for sexual dysfunction. The Cu-IUD users had significant lower scores on physical health, environment and overall quality of life domains of WHOQOL-BREF. More participants who were using the IUD were less satisfied or were not sure about their satisfaction with the method. Conclusion: LARC methods and DMPA are safe and efficient methods that can be used up to the menopause to avoid surgical procedures in case of sterilizations. The use of at least on of these methods, such as LNG-IUS, is enough to avoid unintended pregnancies and their possible consequences. Even not being considered a LARC, DMPA is a safe method and a way to increase its continuation rate is to make the access to this method more practical. The intrauterine methods were not associated with negative effects on sexuality among participants, however, lower scores were found regarding some aspects in quality of life...

show abstract

“…As usuárias de ACO não ganharam mais peso que as usuárias de método não hormonal (p=0,168) mas tiveram aumento de tecido gordo (p<0,01) e percentual de gordura corporal (p<0,01). Em relação ao tecido magro, as usuárias de ACO ganharam mais massa magra que as O caráter reversível do ganho de peso é relevante porque os mecanismos responsáveis pelo ganho significativo de peso corporal, descrito em algumas usuárias do AMPD, não estão totalmente elucidados; além(41,90,101) e ao possível desenvolvimento de resistência à insulina(102,103). Além disso, pode haver concorrente associação com outros fatores como idade, atividade física(90,104,105,106), regulação do apetite e gasto energético(107).…”

unclassified

Avaliação dos efeitos toxicológicos do dimetoato e dimetoato nanoencapsulado em "Danio rerio" (Zebrafish)

Quintino‐Moro¹

View full text Add to dashboard Cite

show abstract

Binge eating and biochemical markers of appetite in new users of the contraceptive depot medroxyprogesterone acetate

Cited by 7 publications

References 27 publications

Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate

Side Effects and Health Benefits of Depot Medroxyprogesterone Acetate

Alguns fatores associados ao uso de métodos intrauterinos e Acetato de Medroxiprogesterona de Depósito

Avaliação dos efeitos toxicológicos do dimetoato e dimetoato nanoencapsulado em "Danio rerio" (Zebrafish)

Contact Info

Product

Resources

About